

# Public Health Link

From the Chief Medical Officer for Wales

**Distribution:** As Appendix 1

**From:** Dr Frank Atherton, Chief Medical Officer for Wales

**Date:** 17 March 2021

**Reference:** CEM/CMO/2021/18

**Category:** Immediate (cascade within 24 hours)

**Title:** Convalescent Plasma In The Management Of Hospitalised Patients With Covid-19

Dear colleagues,

Results from the RECOVERY trial, a randomised, controlled, open-label, adaptive platform trial, showed no significant clinical benefit from treatment with high-titre convalescent plasma in patients hospitalised with COVID-19.

The REMAP-CAP trial, an international randomised, embedded, multifactorial, adaptive platform trial has also announced that no significant benefit was seen from treatment with convalescent plasma (up to two ABO-compatible units administered over 48 hours) in patients requiring organ support in an intensive care setting.

It is therefore now recommended that convalescent plasma is NOT used in the management of hospitalised patients with confirmed or suspected SARS-CoV-2 infection.

Yours sincerely



**DR FRANK ATHERTON**  
Chief Medical Officer

To: Health Boards and NHS Trusts:  
Chief Executives  
Medical Directors  
Nurse Directors  
Hospital Principals and Chief Pharmacists

Cc: NHS Wales Shared Services Partnership (for information)

Cc: Public Health Wales  
Directors of Public Health